US 12,257,315 B1
Cancer treatment method with nanocomposite
Hassan A. Rudayni, Riyadh (SA); Ahmed Aly Allam, Riyadh (SA); Aya FadlAllah Abdelmonem Mohamed, Beni Suef (EG); Mostafa R. Abukhadra, Beni Suef (EG); and Nohan Nasser Abdelfattah Ahmed, Beni Suef (EG)
Assigned to IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY, Riyadh (SA)
Filed by IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY, Riyadh (SA)
Filed on Nov. 18, 2024, as Appl. No. 18/950,997.
Application 18/950,997 is a continuation of application No. 18/778,340, filed on Jul. 19, 2024, granted, now 12,171,841.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); A61K 9/00 (2006.01); A61K 33/243 (2019.01); A61K 47/02 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 47/6923 (2017.08) [A61K 9/0092 (2013.01); A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of cytotoxically treating cancer with a nanocomposite, including:
contacting aluminum silicate nanorods at a concentration of 0.5 to 2 μg/mL with a cancerous sample,
wherein the aluminum silicate nanorods comprise aluminum, iron, magnesium, oxygen, and potassium,
wherein the aluminum silicate nanorods have a longest dimension of 100 to 5500 nm and a diameter of 20 to 250 nm,
wherein the aluminum silicate nanorods are porous with a pore size of 1 to 12 nm,
wherein the aluminum silicate nanorods include cisplatin in an amount of 20 to 300 mg/g, wherein at least a portion of the cisplatin is encapsulated by the aluminum silicate nanorods,
wherein the cancerous sample has a reduced cell viability after the contacting.